Cromolyn Sodium (cromolyn sodium)

The oral aerosol inhaler delivers 800 mcg of cromolyn sodium per metered spray from the mouthpiece. The commercially available aerosol containing 8.1 or 14.2 g of drug delivers at least 112 or 200 metered sprays, respectively; the canister should be discarded after the labeled number of actuations have been used since the correct drug dose per inhalation cannot be assured if used for additional doses.

Although cromolyn sodium is only minimally absorbed (up to 1%) following oral administration, the absorbed portion undergoes renal and biliary elimination. Severe anaphylactic reactions may occur rarely in patients receiving cromolyn sodium, and the manufacturer states that oral dosage of the drug should be reduced in patients with impaired renal or hepatic function. Dosage reduction of cromolyn sodium given via oral inhalation also should be considered in patients with renal or hepatic impairment.

Cromolyn sodium is administered orally and via oral inhalation. The oral concentrate of the drug in ampuls should not be used for oral inhalation therapy nor injected. Proper administration of cromolyn sodium is necessary to obtain optimum results, and it is important that the patient receive careful instruction on the particular dosage form employed.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

• Disease of liver
• Kidney disease with reduction in glomerular filtration rate (GFr)

• Severe hepatic disease
• Severe renal impairment

There is no enhanced messaging for this drug.

Less Frequent

• Pruritus of skin
• Skin rash
• Urticaria

Rare or Very Rare

• Allergic dermatitis
• Allergic dermatitis
• Anaphylaxis
• Anaphylaxis
• Angioedema
• Angioedema
• Arthralgia
• Arthritis
• Bronchospastic pulmonary disease
• Bronchospastic pulmonary disease
• Dizziness
• Dyspnea
• Dyspnea
• Dysuria
• Eosinophilic pneumonia
• Eosinophilic pneumonia
• Headache disorder
• Increased urinary frequency
• Laryngeal edema
• Laryngeal edema
• Muscle weakness
• Myalgia
• Pruritus of skin
• Severe headache disorder
• Skin rash
• Urticaria

More Frequent

• Cough
• Diarrhea
• Dry throat
• Dysgeusia
• Headache disorder
• Nasal congestion
• Nausea
• Sore throat
• Xerostomia

Less Frequent

• Eye tearing
• Hoarseness

Rare or Very Rare

• Abdominal pain with cramps
• Insomnia
• Irritability
• Myalgia
• Nausea

No enhanced messaging available.

No enhanced messaging available.

In animal studies, cromolyn has produced adverse effects on the fetus (e.g., increased resorption, decreased fetal weight) only in very high parenteral doses. Healthy infants have been born to women who received cromolyn throughout pregnancy; nevertheless, there is insufficient evidence to establish the safety of cromolyn in pregnancy. Cromolyn sodium should be used during pregnancy only when clearly needed.

Since it is not known if cromolyn is distributed into milk in humans, the drug should be used with caution in nursing women. Clinicians should weigh the potential benefits to the mother against the potential risks to the infant when considering cromolyn sodium therapy in nursing women.

No enhanced messaging available.